[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fatty-liver-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fatty-liver-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,42,82,105,136,175,196,229,253,273,295,323],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100400642","the-evaluation-of-orange-peel-fermentation-on-body-fat-lowering-efficacy-in-adults-100400642",false,"NCT04496895","The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults","Inclusion Criteria:\n\n1. Adults between the ages of 20 and 65 who are willing to sign the consent form of the subject.\n2. For those with BMI ≥ 24 or fatty liver, male body fat ≥ 25%, female body fat ≥ 30%.\n3. Those who are not pregnant and are willing to cooperate with contraception during the trial period.\n4. No history of cardiovascular disease, history of organ transplantation, history of epilepsy or convulsions, liver and kidney disease, malignant tumor, endocrine disease, mental disease, alcohol or drug abuse, or other major organic diseases (according to medical history).\n\nExclusion Criteria:\n\n1. Pregnant women, people with a history of cardiovascular disease, organ transplantation, epilepsy or convulsions, liver and kidney disease, malignant tumors, endocrine diseases, mental illness, alcohol or drug abuse, and other major organic diseases (according to medical history).\n2. No person who has received major surgery or bariatric surgery (according to medical history).\n3. I have used drugs that affect body fat, waist circumference or significantly increase weight, such as systemic corticosteroids, tricyclic antidepressants, atypical psychiatric drugs, and mood stability in the current or 3 months before participating in the screening Drugs (according to medical history).",true,"ALL","20 Years","65 Years",{"count":20,"type":21},124,"ESTIMATED","INTERVENTIONAL",[24],"NA","To assess whether orange peel fermentation has the effect of reducing body fat in adults",[27,28],"Overweight","Fatty Liver Disease","RECRUITING","2026-05-26",{"date":32,"type":33},"2026-05-29","ACTUAL",{"date":35,"type":33},"2022-11-12",{"date":37,"type":21},"2026-11-30",{"name":39,"class":40},"TCI Co., Ltd.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":65,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100561325","phase-2-digoxin-in-nash-codin-100561325","NCT06588699","Digoxin In NASH (CODIN)","Clinical Trial of Oral Digoxin In NASH (CODIN)","CODIN","Inclusion Criteria\n\n* Stable body weight (≤ 5% self-reported change in body weight) in the 30 days prior to screening\n* Biopsy-confirmed non-alcoholic steatohepatitis (NASH) as defined by the NASH clinical research network (NASH CRN) histological scoring system, with non-alcoholic fatty liver disease score (NAS) ≥4 and with a score ≥1 for each of the three components (steatosis, hepatocellular ballooning, and lobular inflammation) on a liver biopsy performed within 6 months of screening\n* Histological fibrosis stage 2 or 3 based on pathologist evaluation of a liver biopsy performed up to 6 months before screening\n* Agrees to have a liver biopsy performed to assess baseline histology if one has not been performed up to 6 months before screening, and at 24 weeks after randomization Exclusion Criteria\n\nLiver-related:\n\n* Documented causes of chronic liver disease other than NASH\n* History or clinical evidence of cirrhosis or portal hypertension\n* History of positive HBsAg, positive anti-HIV, positive HCV-RNA\n* AST or ALT \\> 5 times upper limit of normal (ULN) at screening\n* Total bilirubin \\> 1.5 mg\u002FdL at screening unless conjugated bilirubin is \\\u003C 1.5 × ULN\n* International normalized ratio (INR) \\> 1.3 at screening\n* Known or suspected alcohol use \\> 20 g\u002Fday for women or \\> 30 g\u002Fday for men\n* Treatment initiation or dose adjustment of vitamin E, pioglitazone, GLP-1RA, or SGLT-2 inhibitors within 30 days of signing the informed consent or 30 days prior to liver biopsy\n* Treatment initiation or anticipated treatment (\\>14 consecutive days) with medications known to affect steatosis (e.g., systemic corticosteroids, tamoxifen, valproic acid, methotrexate, tetracycline or amiodarone) within 30 days of signing the informed consent or 30 days prior to liver biopsy\n\nCardiac related:\n\n* Heart rate less than 60 bpm at screening (visit 1) or at baseline (visit 2)\n* Current diagnosis of severe aortic valve disease\n* History of Accessory arterio-ventricular pathway (e.g., Wolf-Parkinson-White syndrome)\n* History of complete heart block or second degree arterio-ventricular block without pacemaker or implantable cardiac device\n* Current diagnosis of permanent atrial fibrillation\n* Any of the following within the previous 6 months of signing informed consent: myocardial infarction, percutaneous intervention, pacemaker\u002Fimplantable cardiac device implantation, cardiac surgery, or stroke\n* Current use of the following medications: inotropic drugs such as (dopamine, dobutamine, noradrenaline, milrinone), anti-arrhythmics (amiodarone, dofetilide, sotalol, dronedarone, digoxin), parathyroid hormone analog (teriparatide), sympathomimetics (epinephrine, norepinephrine, dopamine), neuromuscular blocking agents (succinylcholine), calcium supplement, nondihydropyridine calcium channel blockers, ivabradine, and disulfiram.\n\nObesity related:\n\n* Treatment initiation (in the 30 days prior to signing the informed consent or 30 days prior to liver biopsy) with orlistat, zonisamide, topiramate, phentermine, bupropion, and naltrexone alone or in combination or any other medication that could promote weight loss in the opinion of the investigator\n* Participation (in the 30 days prior to signing the informed consent or 30 days prior to liver biopsy) in an organized diet-based weight reduction program (e.g., WeightWatchers, Optifast)\n* Recent surgical treatment (\\\u003C6 months of signing informed consent) for obesity\n\nGeneral safety related:\n\n* Presence or history of malignant neoplasms (in the past 5 years prior to screening), except basal and squamous cell skin cancer and any carcinoma in-situ\n* Surgery scheduled or anticipated during the trial period, except for minor surgical procedures, in the opinion of the investigator\n* Language barrier, mental incapacity, unwillingness, or inability to adequately understand or comply with study procedures\n* Known or suspected hypersensitivity to the trial product or related products including allergy to milk, egg, soy, peanuts, and sulfites\n* Recent participation (within 90 days prior to signing the informed consent) in any clinical trial of an approved or non-approved investigational medicinal product\n* Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method\n* Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2\n* TSH \\> 6 mIU\u002FL or \\\u003C 0.4 mIU\u002FL at screening\n* Current use of the following medications: calcium supplementation, parathyroid hormone analog (teriparatide), neuromuscular blocking agents (succinylcholine) and disulfiram.\n* Claustrophobia to an extent that would prevent tolerance of MRI\n* Metallic implant that would prevent MRI examination including, metallic foreign body, aneurysm clips, vascular grafts or cardiac implants, neural stimulator, cochlear implant, metallic contraceptive device, body piercing that cannot be removed, cochlear implant, or any other contraindication to MRI","18 Years","75 Years",{"count":53,"type":21},144,[55],"PHASE2","Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans. The mainstay of treatment for NASH, which was recently renamed metabolic associated steatohepatitis (MASH), involves lifestyle interventions to promote weight loss and to treat comorbidities such as hypertension, hyperlipidemia, and diabetes mellitus. There is thus, a substantial unmet need for pharmacological therapies that are effective for treatment of NASH, especially in those with fibrosis which is the main predictor of disease progression and mortality among NASH patients. The repurposing of presently available drugs would help expedite the search for agents effective in treating NASH. The cardiac glycoside digoxin is currently used in the management of heart failure and supraventricular tachyarrhythmias. The investigators and other groups have demonstrated that digoxin protects the liver from various forms of acute and chronic liver injury. The investigators preliminary data in healthy human subject indicate an immunomodulatory effect of low dose oral digoxin with no adverse side effects. This study proposes to demonstrate the clinical benefits of digoxin on NASH and on liver fibrosis, thus supporting the repurposing of digoxin as treatment for NASH.",[58,59,60,61,62,63,28,64],"NASH","NAFLD","MASH - Metabolic Dysfunction-Associated Steatohepatitis","Mash","MASH With Fibrosis","MASLD","Fatty Liver Disease, Nonalcoholic",[58,66,67,68,69,70,71,59],"MASH","Metabolic dysfunction associated steatohepatitis","Digoxin","Drug repurposing","Liver fibrosis","Fatty liver disease","2026-05-22",{"date":30,"type":33},{"date":75,"type":33},"2025-06-05",{"date":77,"type":21},"2029-01",{"name":79,"class":80},"Yale University","OTHER",2,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":41},"100609460","phase-1-a-research-study-of-a-potential-new-medicine-nnc4005-0001-for-liver-disease-in-adult-participants-with-increased-body-weight-and-liver-fat-100609460","NCT07214870","A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat","A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NNC4005-0001 in Adults","Inclusion Criteria:\n\n* Aged 18-69 years (both inclusive) at the time of signing the informed consent.\n* Body Mass Index (BMI) of 27.0-40.0 kilogram per square meter (kg\u002Fm\\^2) (both inclusive) at screening process.\n* Hepatic fat fraction greater than or equal to (≥) 8% by magnetic resonance imaging proton density fat fraction (MRI-PDFF) within 17 days prior to dosing.\n* No prior or present clinical history of metabolic dysfunction-associated steatohepatitis (MASH) diagnosis.\n\nExclusion criteria:\n\n* Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.\n* Previous or current use of therapies for MASH or antifibrotic therapies (authorised or within aclinical trial).\n* Use of high-dose vitamin E \\[greater than (\\>) 800 international unit (IU) per day\\], glucagon-like peptide-1 (GLP-1) agonists (such as liraglutide, dulaglutide, or semaglutide), glucose-dependent insulinotropic polypeptide (GIP)\u002FGLP-1 agonists (such as tirzepatide), or pioglitazone within 6 months prior to screening.\n* Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) levels greater than or equal (≥) 1.5× Upper Limit of Normal (ULN) at screening.\n* Total bilirubin levels \\> 1.5 times ULN if direct bilirubin is within Normal Limits (WNL) at screening.","69 Years",{"count":91,"type":21},60,[93],"PHASE1","The purpose of this clinical study is to find out if NNC4005-0001 is well-tolerated and safe for people who have increased body weight and increased liver fat. Participants will receive either NNC4005-0001, which is the treatment being tested, or a placebo, which is a treatment that contains no active medicine. The study will last for about for about 7 to 8 months.",[28],"2026-02-09",{"date":98,"type":33},"2026-02-11",{"date":100,"type":33},"2025-10-08",{"date":102,"type":21},"2027-05-14",{"name":104,"class":40},"Novo Nordisk A\u002FS",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":15,"sex":16,"minAge":50,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":41},"100402865","liver-disease-and-other-systemic-diseases-100402865","NCT04525833","Liver Disease and Other Systemic Diseases","The Association of Liver Disease With Other Systemic Diseases, Focus on Diseases Progression, Treatments, and Clinical Outcomes: Analyses From the Hospital Database of Buddhist Tzu Chi Medical Foundation","Inclusion Criteria:\n\n* Individuals who visited the gastroenterology clinics of the Tzu Chi Hospitals, Buddhist Tzu Chi Medical Foundation\n\nExclusion Criteria:\n\n* Age younger than 18 or older than 99 years","99 Years",{"count":114,"type":21},15000,"OBSERVATIONAL","Examine the association of chronic liver diseases (including hepatitis B, hepatitis C, alcoholic liver disease, fatty liver, liver cirrhosis, and hepatocellular carcinoma) with other systemic diseases by retrospectively analyzing the data from the Hospital Database of Buddhist Tzu Chi Medical Foundation.",[118,119,120,121,28,122,123,124,125,126],"Liver Diseases","Humans","Progression","Carcinogenesis","Hepatitis C","Hepatitis B","Hepatocellular Carcinoma","Liver Cirrhoses","Treatment Outcome","2025-09-16",{"date":129,"type":33},"2025-09-19",{"date":131,"type":33},"2020-01-01",{"date":133,"type":21},"2026-12-31",{"name":135,"class":80},"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":18,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":156,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":41},"100598184","gepaktiv-vs-udca-and-ademetionine-in-mafld-with-hepatomegaly-100598184","NCT07068191","Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly","Randomized Comparative Clinical Study of the Dietary Supplement \"Gepaktiv\" (International Name: Phenomenon) in Comparison With Ursodeoxycholic Acid (UDCA) and Ademetionine in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) and Hepatomegaly","HEPACT","Inclusion Criteria:\n\n* Age 18 to 65 years\n* Confirmed diagnosis of metabolic-associated fatty liver disease (MAFLD)\n* Hepatomegaly confirmed by ultrasound (≥3 cm craniocaudal liver enlargement)\n* ALT level between 90-150 U\u002FL\n* Steatosis ≥260 dB\u002Fm by FibroScan (CAP)\n* Fibrosis ≥11 kPa by transient elastography (FibroScan)\n* Ability to comply with study procedures\n* Signed informed consent\n\nExclusion Criteria:\n\n* Liver cirrhosis or hepatocellular carcinoma\n* Pregnancy or lactation\n* Known allergy to any of the study medications or supplement components\n* Gallstones or biliary obstruction\n* Shrunken liver on imaging\n* Hepatic cysts (simple liver cysts\u002Fbiliary cysts)\n* Liver nodules (focal liver lesions)",{"count":145,"type":21},90,[24],"This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).\n\nKey points:\n\n* Participants will receive either Gepaktiv, UDCA, or Ademetionine for 15 days\n* Doctors will monitor liver health through blood tests and ultrasound scans\n* The study will check if Gepaktiv helps improve liver function as effectively as standard treatments.\n\nMain measurements:\n\n* Changes in liver enzyme levels (ALT, AST)\n* Reduction in liver size\n* Improvement in fat accumulation (steatosis) measured by FibroScan This research may provide evidence for a new natural option to support liver health.Data analysis will be done by an independent biostatistics",[149,150,151,152,153,154,155,28],"Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)","Hepatomegaly","Nonalcoholic Fatty Liver (NAFL)","Nonalcoholic Fatty Liver Disease (NAFLD)","Fatty Liver","Fatty Liver, Alcoholic","Fatty Liver, Nonalcoholic",[150,157,158,159,160,161,162,163,164,165,153],"Gepaktiv","Metabolic dysfunction-associated fatty liver disease (MAFLD)","metabolic dysfunction-associated steatotic liver disease (MASLD)","Nonalcoholic fatty liver disease (NAFLD)","liver diseases","Nonalcoholic fatty liver (NAFL)","Liver","Liver steatosis","Dietary supplements","2025-07-19",{"date":168,"type":33},"2025-07-23",{"date":170,"type":33},"2025-06-19",{"date":172,"type":21},"2025-08",{"name":174,"class":80},"Phenomen Pharma",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":41},"100577779","livq-box-parameters-in-the-diagnosis-of-liver-inflammation-100577779","NCT06802731","LivQ-box® Parameters in the Diagnosis of Liver Inflammation","A Multicenter Study on the Application of LivQ-box® Parameters in the Diagnosis of Liver Inflammation in Patients with Non-alcoholic Fatty Liver Disease","Inclusion Criteria:\n\n* Patients diagnosed with NAFLD according to The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases;\n* Age over 18 years old, gender not limited;\n* Not combined with liver diseases (such as viral hepatitis, drug-induced liver injury, autoimmune liver disease);\n* Perform iLivTouch examination within ± 14 days of liver pathology examination;\n* No history of excessive alcohol consumption (converted to ethanol:\\\u003C140g\u002Fweek for males,\\\u003C70g\u002Fweek for females);",{"count":183,"type":21},365,"To evaluate the correlation between LivQ-box® parameters carried by iLivTouch and liver inflammation in patients with NAFLD, as well as the diagnostic value of liver inflammation of different severity levels.",[186,28],"Liver Inflammation","2025-01-24",{"date":189,"type":33},"2025-01-31",{"date":191,"type":33},"2024-01-01",{"date":193,"type":21},"2025-06-30",{"name":195,"class":40},"Wuxi Hisky Medical Technology Co Ltd",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":15,"sex":204,"minAge":50,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":41},"100573867","the-role-of-sugars-in-fat-accumulation-in-the-liver-100573867","NCT06751862","The Role of Sugars in Fat Accumulation in the Liver","The Effect of Simple Carbohydrates on the Development of Non-alcoholic Fatty Liver Disease (FROGLOSA)","FROGLOSA","Part A\n\nInclusion Criteria:\n\n* male volunteers - 15 nonobese subjects (Body Mass Index (BMI) \\\u003C 30 kg\u002Fm2) and 15 obese subjects (BMI ˃ 30 kg\u002Fm2)\n* 18 - 70 years old\n\nExclusion Criteria:\n\n* diabetes mellitus (fasting glucose above 7 mmol\u002Fl, 2-hour glucose after oGTT above 11.1 mmol\u002Fl, or antidiabetic treatment)\n* other serious illnesses (cardiovascular disease, cancer, etc.)\n* alcohol consumption ˃ 30 g\u002Fday\n* fructose intolerance\n* use of drugs affecting lipid metabolism\n\nPart B\n\nInclusion Criteria:\n\n* male volunteers with hepatic fat content higher than 6.2% and less than 16.5%, which corresponds to steatosis grade 2 (S2)\n* 18 - 70 years old\n\nExclusion Criteria:\n\n* diabetes mellitus (fasting glucose above 7 mmol\u002Fl, 2-hour glucose after oGTT above 11.1 mmol\u002Fl, or antidiabetic treatment)\n* other serious illnesses (cardiovascular disease, cancer, etc.)\n* alcohol consumption ˃ 30 g\u002Fday\n* use of drugs affecting lipid metabolism\n* intolerance of MR examination (claustrophobia, metal implants, etc.).","MALE","70 Years",{"count":207,"type":21},40,[24],"This interventional study has 2 parts. In the part A of the project, we will determine how the acute changes in hepatic fat content (HFC) after high-fat load (150 g of fat) are affected by co-administration with three doses of glucose, fructose, and sucrose. HFC in non-obese and obese male volunteers will be measured by magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) before and at the end of 6-hour intervention. The changes in triglycerides (TG), non-esterified fatty acids (NEFA), insulin and glucose will be also measured throughout the experiments. It can be expected that most of the obese subjects will also have a non-alcoholic fatty liver disease (NAFLD) and we will be therefore able to compare the HFC response between subjects with normal liver fat content and those with steatosis.\n\nOur previous results (doi: 10.26402\u002Fjpp.2021.1.05) clearly pointed out that glucose, contrary to fructose, prevents the storage of fat in the liver and that such an effect could be observed even after six hours. In the part B, we will therefore eliminate fructose from the diet of subjects with NAFLD of steatosis grade 2 for seven days - such an intervention will be isocaloric and fructose\u002Fsucrose will be replaced by starch or by glucose. The HFC content will be measured again by MRS and MRI after 168 hours. Very low density lipoprotein (VLDL), that transport TG out from the liver, will be isolated before and after intervention from the plasma obtained after overnight fasting. The analysis of lipid profile of the liver fat by MRS and fatty acid profile of TG in VLDL should provide an information on the role of de novo lipogenesis (DNL) in changes of HFC.\n\nIn the part A of the project we will aim\n\n* to compare the response of HFC after high-fat load to repeated doses of glucose, fructose, and sucrose (3 x 50 g in two-hour intervals)\n* to compare such a response between non-obese and obese-subjects\n\nIn the part B of the project we will aim\n\n* to find out whether short-term (7 days) restriction of fructose from the diet will decrease HFC in subjects with NAFLD\n* to find out whether such an intervention affects fatty acid profile of hepatic TG evaluated by MRS and by fatty acid profile of TG in VLDL - in this way we can estimate whether DNL is suppressed after fructose withdrawal\n* to further corroborate such an aim, we will also compare the fatty acid profile of plasma NEFA and that of TG in VLDL",[28],[212,213,214,215,216,217,218],"hepatic fat content","magnetic resonance","fatty liver disease","diet intervention","fructosa","glucosa","sucrosa","2024-12-18",{"date":221,"type":33},"2024-12-30",{"date":223,"type":33},"2024-06-20",{"date":225,"type":21},"2027-03",{"name":227,"class":228},"Institute for Clinical and Experimental Medicine","OTHER_GOV",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":252},"100506947","nac--nafld-and-cushing-100506947","NCT05881005","NAC- NAFLD and Cushing","Prévalence De La Stéato-fibrose Hépatique Dans Le Syndrome De Cushing","NAC","Inclusion Criteria:\n\n* Age \\> 18 years\n* Active Cushing's syndrome\n\nExclusion Criteria:\n\n* Other common causes of chronic liver disease (HBV, HCV, haemochromatosis, alcohol)\n* Contraindication to MRI",{"count":238,"type":21},100,[24],"Cushing's Syndrome is a rare disease resulting from prolonged exposure to high levels of circulating cortisol. Clinical manifestations are variable but many patients present a metabolic syndrome (abdominal obesity, insulin resistance, dyslipidemia, hypertension). With regard to the liver, experimental data have shown that excess cortisol leads in an increase in lipogenesis and a reduction in the oxidation of fatty acids. This, in association with an accumulation of visceral adipose tissue and deregulation of adipokines, may contribute to the development of hepatic steatosis in animals. However, few data is available in humans with only one study of 50 patients with Cushing's syndrome estimating the prevalence of hepatic steatosis at 20%.\n\nNAFLD (Non-Alcoholic Fatty Liver Disease), is defined as the presence of hepatic steatosis in the absence of secondary causes of intrahepatic fat accumulation. It is a heterogeneous disease ranging from simple liver steatosis, whose prognosis is generally considered to be benign, to inflammation (NASH, Non-Alcoholic Steato-Hepatitis) which may progress to fibrosis, cirrhosis and an increased risk of hepatocellular carcinoma. The prognosis for NAFLD is mainly related to the severity of hepatic fibrosis.\n\nIn Cushing's syndrome, normalization of cortisol production is the most effective strategy to improve co-morbidities associated with hypercortisolism. However, some of these complications, especially the metabolic co morbidities, could not be completely reversible and no data is available about resolution of hepatic steatosis.",[242,28],"Cushing Syndrome","2024-12-11",{"date":245,"type":33},"2024-12-16",{"date":247,"type":33},"2023-09-28",{"date":249,"type":21},"2027-09-28",{"name":251,"class":228},"University Hospital, Angers",6,{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":63,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":205,"enrollmentInfo":259,"targetDuration":261,"studyType":115,"phases":4,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":41},"100571477","assessment-of-fibbroscan-in-diagnosing-masld-among-the-chinese-population-with-obesity-100571477","NCT06720766","Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity","Inclusion Criteria:\n\n1. Patients aged 18 years or older who provided written informed consent\n2. Patients who schedule to undergo bariatric surgery and a liver biopsy (LB) for the investigation of suspected MASLD\n3. Patients who schedule to undergo FibroScan examination\n\nExclusion Criteria:\n\n1. Patients with ascites or pregnant women\n2. Patients with any active implantable medical device (such as a pacemaker or defibrillator)\n3. Patients who have undergone liver transplantation\n4. Patients with cardiac failure and\u002For significant valvular disease\n5. Patients with haemochromatosis\n6. Patients who have refused to undergo LB or blood tests\n7. Patients with a confirmed diagnosis of active malignancy, or other terminal disease\n8. Patients participating in another clinical trial within the preceding 30 days",{"count":260,"type":21},600,"1 Month","The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity. However, there are still considerable uncertainties regarding the potential influence of confounding factors and the optimal application of cut-off values for obesity.\n\nThe goal of this observational study is to learn about the optimal application of cut-off values of for Chinese people with obesity.",[28],"2024-12-02",{"date":266,"type":33},"2024-12-06",{"date":268,"type":33},"2023-10-24",{"date":270,"type":21},"2025-03-31",{"name":272,"class":80},"The Third People's Hospital of Chengdu",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":205,"enrollmentInfo":280,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":285,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":4},"100569229","metabolic-associated-fatty-liver-disease-in-patients-with-chronic-glomerular-disease-100569229","NCT06691529","Metabolic Associated Fatty Liver Disease in Patients With Chronic Glomerular Disease","The Association of Metabolic Associated Fatty Liver Disease in Patients With Chronic Glomerular Disease","Inclusion Criteria:\n\n* All CKD patient aging between (18-70) years with known tubule-glomerular diseases.\n* At any eGFR.\n* All CKD patient have either type I\u002FII DM associated with CKD .\n\nExclusion Criteria:\n\n* CKD patients of Unknown etiology.\n* CKD patients with liver cirrhosis.\n* CKD patients secondry to documented diabetic nephropathy.\n* Patients with previous\u002Fcurrent HBV or HCV.\n* Pregnant CKD patients.\n* Patient commencing any hepatotoxic medication.",{"count":281,"type":21},500,"The association of metabolic associated fatty liver disease in patients with chronic glomerular disease",[28,284],"Chronic Glomerular Disease","NOT_YET_RECRUITING","2024-11-15",{"date":288,"type":33},"2024-11-18",{"date":290,"type":21},"2024-12",{"date":292,"type":21},"2026-03",{"name":294,"class":80},"Assiut University",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":16,"minAge":302,"maxAge":303,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":306,"briefSummary":307,"conditions":308,"keywords":309,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":41},"100561117","synbiotics-impact-on-insulin-and-tnf--in-mafld-a-gut-microbiota-profile-analysis-100561117","NCT06585982","Synbiotics Impact on Insulin and TNF-α in MAFLD: a Gut Microbiota Profile Analysis","Gut Microbiota Profile Analysis and Randomized Controlled Trials (RCT) Study of the Effect of Synbiotics on Insulin and TNF-α in Metabolic Dysfunction -Associated Fatty Liver Disease (MAFLD)","Inclusion Criteria:\n\n1. Adult patients aged 25-55 years\n2. Patients are willing to become research respondents after filling out informed consent\n3. Patients can and are willing to consume supplements orally within a predetermined time\n4. Patients are willing to record compliance with taking supplements in a diary that has been provided\n5. Patients diagnosed with MAFLD by FibroScan interpreted by a specialist in gastroenterology-hepatology with a CAP score ≥263 dB\u002Fm\n\nExclusion Criteria:\n\n1. Patients with hepatitis (hepatitis B, hepatitis C, and autoimmune hepatitis) and alcoholic liver disease, cirrhosis of the liver\n2. Patients who are pregnant, or breastfeeding or in a programme to become pregnant during participation in this study.\n3. Patients with a history of alcohol consumption \\>40 g\u002Fday.\n4. Patients with a history of decompensated disease including ascites, encephalopathy, variceal haemorrhage\n5. Patients with Hepatocellular Carcinoma (HCC)\n6. Patients with a history of bowel resection or bariatric surgery Patients with chronic inflammatory bowel disease (IBD)\n7. Patients with a history of antibiotic use or probiotic\u002Fprebiotic\u002Fsynbiotic consumption in the past 1 month\n8. Use of Vitamin E and omega-3 fatty acids\n9. Patients who were not hospitalised in the last month and therefore did not have any food restrictions related to their illness.","25 Years","55 Years",{"count":305,"type":21},50,[24],"Primary Objective: To analyze the effect of synbiotic supplementation on metabolic profile, insulin and TNF-α and gut microbiota changes in patients with Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD).\n\nResearch question: Are there any changes in metabolic profile, Insulin and TNF-α and gut microbiota changes in MAFLD patients after synbiotic supplementation\n\nParticipants will:\n\n* Treatment group given supplementation and the control group will be given placebo at a dose of 2x1 tablet for 12 weeks.\n* Patients will visit the hospital every 28 days for up to 4 months for control and follow-up supplementation.\n* patients will be given a supplement consumption compliance logbook and a food record logbook used to record food consumption filled in by the patient.",[28],[310,311,312,313],"Metabolic dysfunction-associated fatty liver disease","Gut Microbiota","Metabolic profile","Synbiotic","2024-11-07",{"date":316,"type":33},"2024-11-12",{"date":318,"type":33},"2024-03-04",{"date":320,"type":21},"2025-03-07",{"name":322,"class":80},"Universitas Diponegoro",{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":332,"conditions":333,"keywords":335,"overallStatus":285,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":4},"100561361","metabolic-syndrome-and-fatty-liver-disease-among-egyptian-patients-with-chronic-hbv-100561361","NCT06589167","Metabolic Syndrome and Fatty Liver Disease Among Egyptian Patients with Chronic HBV","Metabolic Dysfunction Among Egyptian Patients with Chronic HBV","Inclusion Criteria:\n\n* Age above 18 years.\n\nExclusion Criteria:\n\n* Age below 18 years.\n* Patients with combined HBV,HCV,HIV.\n* Patients refused to contribute in this study.","60 Years",{"count":238,"type":21},"1. investigate the Prevalence of combined hepatic steatosis in patients with chronic HBV.\n2. to evaluate clinical characteristics of chronic HBV patients combined with metabolic syndrome and hepatic steatosis",[334,28],"Metabolic Syndrome",[336,337,338],"Metabolic syndrome","Nonalcoholic fatty liver disease","hepatic steatosis","2024-09-05",{"date":341,"type":33},"2024-09-19",{"date":343,"type":21},"2024-09-07",{"date":345,"type":21},"2025-10",{"name":294,"class":80}]